ID: ALA3908921

Max Phase: Preclinical

Molecular Formula: C54H74Cl4N8O12S2

Molecular Weight: 1233.18

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2ccc(S(=O)(=O)NCCOCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCOCCNS(=O)(=O)c3ccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)cc3)cc2)C1

Standard InChI:  InChI=1S/C54H74Cl4N8O12S2/c1-65-35-47(45-31-41(55)33-51(57)49(45)37-65)39-5-9-43(10-6-39)79(69,70)63-17-21-75-25-29-77-27-23-73-19-15-61-53(67)59-13-3-4-14-60-54(68)62-16-20-74-24-28-78-30-26-76-22-18-64-80(71,72)44-11-7-40(8-12-44)48-36-66(2)38-50-46(48)32-42(56)34-52(50)58/h5-12,31-34,47-48,63-64H,3-4,13-30,35-38H2,1-2H3,(H2,59,61,67)(H2,60,62,68)/t47-,48-/m0/s1

Standard InChI Key:  ZPANXMBRBMXECG-CRKOEVGVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1233.18

Molecular Weight (Monoisotopic): 1230.3622

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1.  (2013)  Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders, 

Source

Source(1):

• Patent Bioactivity Data